Budesonide
Product Images NDC 68258-8922

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 68258-8922). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure For Budesonide (74af92d2 6539 4dc3 A09a Cb43e011668a 01)

Chemical structure of Budesonide showing its molecular formula C25H34O6 and molecular weight of 430.5. The diagram illustrates the steroid framework and functional groups characteristic of Budesonide.*

FDA Label Image

Figure 2 (74af92d2 6539 4dc3 A09a Cb43e011668a 02)

A line graph showing mean change from baseline in nighttime asthma symptoms over 12 weeks for three groups: placebo, 0.25 mg twice daily, and 0.5 mg twice daily. The x-axis represents time intervals from baseline to week 12, and the y-axis represents mean change in symptoms. Data points indicate symptom reduction over time, with p-values provided for 0.25 mg (0.022) and 0.5 mg (0.021) dosages.*

FDA Label Image

Figure 3 (74af92d2 6539 4dc3 A09a Cb43e011668a 03)

A line chart showing mean change from baseline in nighttime asthma symptoms over various weeks. The x-axis represents time intervals (baseline through weeks 0-12) and the y-axis shows the mean change from baseline. Lines compare placebo and three dosing regimens (0.25 mg once daily, 0.25 mg twice daily, and 0.5 mg twice daily). The chart includes p-values for each dosing group versus placebo.*

FDA Label Image

Figure 4 (74af92d2 6539 4dc3 A09a Cb43e011668a 04)

An instructional illustration showing a pair of hands opening a blister pack of tablets or capsules. One hand holds the blister package while the other hand peels back the foil or pushes a tablet through the blister cavity, demonstrating how to access the medication inside.*

FDA Label Image

Figure 5 (74af92d2 6539 4dc3 A09a Cb43e011668a 05)

An instructional illustration depicting a hand holding a brown vial or container with the thumb and index finger. The illustration shows a curved arrow around the container, indicating a twisting or turning motion. The figure is labeled 'Figure 2'.*

FDA Label Image

Figure 6 (74af92d2 6539 4dc3 A09a Cb43e011668a 06)

Illustration showing a hand holding a vial while a second hand is using a dropper or similar tool to withdraw liquid from the vial. Labeled as Figure 3, it depicts the process of extracting medication from a container, likely for dosing or administration purposes.*

FDA Label Image

Figure 7 (74af92d2 6539 4dc3 A09a Cb43e011668a 07)

An instructional illustration showing two hands, where one hand is holding a small container or vial and the other hand is removing or placing a cap on the vial. The image likely demonstrates a step in the preparation or administration of Budesonide.*

FDA Label Image

Ndc 68258-8922-05 (Ndc 68258 8922 05 Teva)

Label for Budesonide 0.5 mg/2 mL inhalation suspension in 5 unit-dose vials. Each vial contains 2 mL of sterile suspension with 0.5 mg micronized Budesonide. The product is marked RX only and packaged by Dispensing Solutions, Inc., Santa Ana, CA. Storage instructions specify 68°-77°F and protection from light; use is restricted to oral inhalation via jet nebulizer.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.